The price cap would have lowered costs for Enbrel, an immunosuppressant drug made by Amgen.
Articles on Prescription drug costs
Displaying all articles
High prescription drug costs are leaving many patients frustrated and unable to afford their medications.
Despite the historic passage of pharmacare legislation, its rollout remains uncertain. While some provinces have already reached deals with Ottawa, others remain in discussions.
As the middlemen between drug companies and insurers, PBMs are shoo-ins as the villains behind high drug prices. But they do play a useful role in the health marketplace.
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
A new law will let Medicare bargain for the first time. But a health policy scholar explains why it’s unlikely to make much of a difference in how much seniors – or anyone else – pays for their meds.
About 1 in 4 Americans with diabetes who need insulin struggle to pay for this lifesaving drug.
Any pharmacare plan that aims to remove financial barriers to treatment and eliminate inequities should prioritize those who face the highest out-of-pocket drug costs, such as people with disabilities.
Drug prices for many life-saving drugs have skyrocketed in recent years. The reasons may surprise you.
High prescription drug costs are a widespread concern for consumers and policymakers. For patients who need specialty drugs, though, the problem is even worse, with no relief in sight.
As drug prices soar, consumers look for cheaper generics. A recent study showed safety issues in some generics made abroad, however, suggesting that the FDA’s honor system may not be enough to ensure safety.
Politicians and even HHS are now discussing ways to allow US consumers to buy drugs from Canada. Here’s why it’s not as simple as it seems.
Presidential candidates and the current president have all talked about ways to lower drug costs, but experts know it is going to take more than politics to change how drugs are priced in the US.
Presidential candidates have been proposing plans to expand health coverage, lower prescription drug costs and make hospital bills more transparent. But few get to the real problem. Here’s why.
Top contributors
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate Professor of Public Health, The Ohio State University
-
Assistant Professor of Medicine, University of Pittsburgh
-
Research Coordinator, Centre for Health Services and Policy Research and School of Rehabilitation Therapy, Queen's University, Ontario
-
Associate Professor of Pharmacy Administration, University of Mississippi
-
Associate Professor of Surgery and Public Policy, University of Virginia
-
Professor of Economics, University of Calgary
-
Clinical Professor of Pharmacy Practice, University of Mississippi
-
Associate Professor, School of Public Health, University of Alberta
-
Associate Professor & Program Director, Public Health Policy & Management, University of Arizona
-
Director of the Health Justice Institute at the Schulich School of Law, Dalhousie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Christopher McCabe is a Friend of The Conversation.
Professor of Health Economics, Queen's University Belfast
-
Professor, School of Population and Public Health, University of British Columbia
-
Professor, School of Rehabilitation Therapy, Queen's University, Ontario